Outcome of Allogenic Hematopoietic Stem Cell Transplantation in Myelofibrosis: A Single-Center Retrospective Analysis

Abstract

<h3>Objective</h3> To study clinical outcome in patients with Myelofibrosis undergoing Allogenic hematopoietic stem cell transplantation. <h3>Introduction</h3> Allogenic hematopoietic stem cell transplantation (HSCT) is currently the only curative treatment option for Myelofibrosis (MF). Despite the benefit of long-term, relapse- free survival with HSCT, it can be associated with substantial treatment-related morbidity and mortality. Therefore careful patient counseling and accurate patient selection is mandatory. <h3>Methods</h3> This is an observational retrospective study including patients with previous diagnosis of MF (primary or secondary) who underwent Allogenic HSCT at a tertiary care centre in Northern India between June 2012 and September 2019. Pre-transplant DIPSS and HCT-CI scores were applied. The primary end points were overall survival and disease free survival (OS and DFS), and secondary end points were post-transplant complications (graft-versus-host-disease [GVHD], graft failure [GF], CMV reactivation [CMV]). (Table 1) <h3>Results</h3> Outcome of SCT given in table 2. <h3>Conclusion</h3> Myelofibrosis remains a very challenging condition to treat with a poor prognosis. Our study shows reduced toxicity conditioning provides a good DFS and OS. Thus it should be offered upfront to patients with high DIPSS scores. Sepsis remains the predominant cause of mortality in our cohort.